Faraj Nakhleh
Presidente presso EMERGIA INC.
Profilo
Faraj M.
Nakhleh is currently the President & Chief Executive Officer at Trak Concepts, Inc. since 2008 and the Chairman at Emergia, Inc. since 2022.
Previously, he served as the Director at NTI Newmerical, Inc. and as a Director at Ambrilia Biopharma, Inc. from 2010 to 2011.
He also worked as a Partner at Raymond Chabot Grant Thornton LLP.
Mr. Nakhleh holds a graduate degree from McGill University and an undergraduate degree from Robert College.
Posizioni attive di Faraj Nakhleh
Società | Posizione | Inizio |
---|---|---|
EMERGIA INC. | Presidente | 16/04/2024 |
Trak Concepts, Inc. | Amministratore Delegato | 09/10/2009 |
Precedenti posizioni note di Faraj Nakhleh
Società | Posizione | Fine |
---|---|---|
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Direttore/Membro del Consiglio | 08/04/2011 |
Raymond Chabot Grant Thornton LLP
Raymond Chabot Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Raymond Chabot Grant Thornton LLP engages in the provision of tax, recovery and organization, management consulting, financial advisory, digital and technology, assurance and human resource consulting services. It serves the tourism, leisure and culture, natural resources, mining and forestry, manufacturing, and retail and distribution industry. The company was founded in 1948 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
NTI Newmerical, Inc.
NTI Newmerical, Inc. Packaged SoftwareTechnology Services NTI Newmerical, Inc. develops advanced CFD multi-disciplinary simulation software for the aeronautics, automotive, marine and power and process industries. It develops and provides in-flight icing simulation software and associated design, testing and certification services to aerospace companies desirous to apply safety standards that meet and exceed regulations. It was founded by Wagdi G. Habashi is headquartered in Montreal, Canada. | Direttore/Membro del Consiglio | - |
Formazione di Faraj Nakhleh
McGill University | Graduate Degree |
Robert College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
EMERGIA INC. | Finance |
Aziende private | 4 |
---|---|
NTI Newmerical, Inc.
NTI Newmerical, Inc. Packaged SoftwareTechnology Services NTI Newmerical, Inc. develops advanced CFD multi-disciplinary simulation software for the aeronautics, automotive, marine and power and process industries. It develops and provides in-flight icing simulation software and associated design, testing and certification services to aerospace companies desirous to apply safety standards that meet and exceed regulations. It was founded by Wagdi G. Habashi is headquartered in Montreal, Canada. | Technology Services |
Raymond Chabot Grant Thornton LLP
Raymond Chabot Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Raymond Chabot Grant Thornton LLP engages in the provision of tax, recovery and organization, management consulting, financial advisory, digital and technology, assurance and human resource consulting services. It serves the tourism, leisure and culture, natural resources, mining and forestry, manufacturing, and retail and distribution industry. The company was founded in 1948 and is headquartered in Montreal, Canada. | Commercial Services |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Trak Concepts, Inc. |
- Borsa valori
- Insiders
- Faraj Nakhleh